Recommendations for Intensive Blood Pressure Lowering in High-Risk Patients, the Canadian Viewpoint

Hypertension

Volumn 68, Issue 1, 2016, Pages 3-5

  Padwal, Raj ^a,b   Rabi, Doreen M ^c   Schiffrin, Ernesto L ^d  

^a UNIVERSITY OF ALBERTA   (Canada)

^b MAZANKOWSKI ALBERTA HEART INSTITUTE   (Canada)

^c UNIVERSITY OF CALGARY   (Canada)

^d MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; LONG ACTING DRUG;

AGED; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; DIABETES MELLITUS; HEALTH CARE; HIGH RISK PATIENT; HUMAN; META ANALYSIS (TOPIC); PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; VERY ELDERLY; CANADA; CLASSIFICATION; EVIDENCE BASED PRACTICE; HYPERTENSION; MEDICATION THERAPY MANAGEMENT; PROCEDURES; RISK ASSESSMENT; STANDARDS; TOTAL QUALITY MANAGEMENT;

ANTIHYPERTENSIVE AGENTS; CANADA; EVIDENCE-BASED PRACTICE; HUMANS; HYPERTENSION; MEDICATION THERAPY MANAGEMENT; PRACTICE GUIDELINES AS TOPIC; QUALITY IMPROVEMENT; RISK ASSESSMENT;

EID: 84966392106     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.116.07573     Document Type: Review

References (12)

1. The SPRINT Research Group. A randomized trial of intensive versus standard blood pressure control. N Engl J Med. 2015;373:2103-2116.
2. Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, Chalmers J, Rodgers A, Rahimi K. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387:957-967. doi: 10.1016/S0140-6736(15)01225-8.
3. Xie X, Atkins E, Lv J, et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet. 2016;387:435-443. doi: 10.1016/S0140-6736(15)00805-3.
4. McAlister FA. The Canadian Hypertension Education Program-a unique Canadian initiative. Can J Cardiol. 2006;22:559-564.
5. Feldman RD, Campbell N, Larochelle P, Bolli P, Burgess ED, Carruthers SG, Floras JS, Haynes RB, Honos G, Leenen FH. 1999 Canadian recommendations for the management of hypertension. CMAJ. 1999;161:S1-S17.
6. Leung AA, Nerenberg K, Daskalopoulou SS, et al. Hypertension Canada's 2016 CHEP Guidelines for blood pressure measurement, diagnosis, assessment of risk, prevention and treatment of hypertension. Can J Cardiol. 2016;32:569-588. doi: 10.1016/j.cjca.2016.02.066.
7. Cloutier L, Daskalopoulou SS, Padwal RS, Lamarre-Cliche M, Bolli P, McLean D, Milot A, Tobe SW, Tremblay G, McKay DW, Townsend R, Campbell N, Gelfer M. A New Algorithm for the Diagnosis of Hypertension in Canada. Can J Cardiol. 2015;31:620-630. doi: 10.1016/j. cjca.2015.02.014.
8. Rabi DM, Padwal R, Tobe SW, Gilbert RE, Leiter LA, Quinn RR, Khan N; Canadian Hypertensive Education Program; Canadian Diabetes Association. Risks and benefits of intensive blood pressure lowering in patients with type 2 diabetes. CMAJ. 2013;185:963-967. doi: 10.1503/cmaj.120112.
9. ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362:1575-1585.
10. Margolis KL, O'Connor PJ, Morgan TM, Buse JB, Cohen RM, Cushman WC, Cutler JA, Evans GW, Gerstein HC, Grimm RH Jr, Lipkin EW, Narayan KM, Riddle MC Jr, Sood A, Goff DC Jr. Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial. Diabetes Care. 2014;37:1721-1728. doi: 10.2337/dc13-2334.
11. Gueyffier F, Bulpitt C, Boissel JP, Schron E, Ekbom T, Fagard R, Casiglia E, Kerlikowske K, Coope J. Antihypertensive drugs in very old people: a subgroup meta-analysis of randomised controlled trials. INDANA Group. Lancet. 1999;353:793-796.
12. Beckett NS, Peters R, Fletcher AE, et al; HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358:1887-1898. doi: 10.1056/NEJMoa080136